Processing

Lonza collaborates on commercial supply manufacturing for anti-coagulation antidote

Portola Pharmaceuticals and Lonza announced a partnership to start a commercial supply of Portola’s recently approved​, second generation Andexxa (andexanet alfa, recombinant coagulation factor Xa). Portola’s Andexxa is an antidote for the medications Xarelto (rivaroxaban) and Eliquis (aprizaban), when the reversal of anticoagulation is needed for uncontrolled bleeding. “Portola has Czytaj więcej…